BROSSARD, QUEBEC--(Marketwired - Aug. 21, 2014) - Diagnos Inc. ("DIAGNOS" or "the Corporation") (TSX VENTURE:ADK), a leader in healthcare technical services including screening, software and algorithm development, data analysis, and image processing, announced today the signing of a contract with a large global pharmaceutical company for a screening project in Argentina.
"We are pleased to have received so much support from the global headquarters of our client in the UAE and India; they have watched our successful programs grow and are asking us to expand into other countries. The purpose of this project is to prove that our screening program works in an Argentinean environment. From our experience, once a project has proven itself with one or two screening units in a region, the number of screening units tends to increase exponentially. For example, we started with a similar pilot project of one screening unit in the UAE in 2011, and we now have 14 screening units there," said André Larente, Diagnos' President.
Founded in 1998, DIAGNOS is a publicly traded Canadian corporation, with a mission to commercialize technologies to improving decision making processes in different sectors. DIAGNOS offers products, services, and solutions to clients in a variety of fields including healthcare and natural resources.
About DIAGNOS Healthcare
DIAGNOS Healthcare is a business division with DIAGNOS Inc., achieving international recognition as leader in healthcare technical services including, screening, software and algorithm development, data analysis, and image processing. Through its Healthcare division, DIAGNOS offers turn-key diabetic retinopathy screening services to patients in various locations around the world.
Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For further information on DIAGNOS, please visit our website at www.diagnos.com or the SEDAR website at www.sedar.com.